Clin2
NCT07342764Possibly a fitNot yet recruiting

Comparing dapagliflozin versus metformin for antipsychotic weight gain

Antipsychotic-induced Weight Gain (AIWG)Antipsychotic-induced Weight Gain

Treatments studied

Part of Mental health clinical trials.

This study compares two medicines, dapagliflozin and metformin, to see which is better at helping people who have gained weight from antipsychotic medications. Both are already approved for diabetes but may also help with weight loss.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
110 people
Ages
16 years to 60 years
Study type
Interventional

Who can take part

  • You are 16 or older and have a mental health condition (like schizophrenia, bipolar disorder, or depression) for which you take antipsychotic medication.
  • You have been on the same antipsychotic for at least 3 months.
  • You have gained weight because of the antipsychotic — either a 7% weight gain since starting it or a BMI over 25 with weight gain linked to the medication.
  • You do not have diabetes or polycystic ovary syndrome (PCOS).
  • You are not currently taking metformin, dapagliflozin, or similar medicines for weight loss or diabetes.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05744479Recruiting· Phase 4
Metformin to reduce weight gain from antipsychotic medicines

This trial tests whether metformin can help adults with intellectual disability who gained weight from long-term antipsychotic medicines. If you qualify, you may be assigned metformin to improve weight and related health measures.

Toronto, Ontario
NCT07311551Not yet recruiting· Phase 4
Comparing two diabetes drugs for weight management

This trial compares two medications, dapagliflozin and empagliflozin, to see which works better and is safer for people with type 2 diabetes and a high body mass index (BMI). If you are an adult with type 2 diabetes and a BMI of 23 or higher, this study might help find a treatment that also supports weight loss.

NCT06875193Recruiting· Phase 4
Comparing dapagliflozin vs pioglitazone for type 2 diabetes

This study is testing two different diabetes pills—dapagliflozin or pioglitazone—in people with type 2 diabetes. The goal is to see which one works better when added to your current metformin and DPP-4 inhibitor. You may qualify if your blood sugar is not well controlled with your current medications.

Seoul
NCT06762314Recruiting· Phase 2
Empagliflozin or semaglutide for overweight people with type 1 diabetes

This study tests two different medicines (empagliflozin or semaglutide) added to your usual insulin to see if they help with blood sugar control and weight loss in people with type 1 diabetes who are overweight or have obesity. It may be a good fit if your diabetes is not well controlled with insulin injections alone.

Tanta
NCT07336797Recruiting· Phase 2
Empagliflozin for weight and metabolism in HIV

This trial tests if empagliflozin, a diabetes medicine, can improve weight and metabolism in people with HIV who take dolutegravir and have a high body mass index (BMI). It may help reduce weight gain linked to HIV treatment.

Cairo
NCT06590298Not yet recruiting· Phase 4
Aripiprazole for weight and metabolism in women on antipsychotics

This study tests whether adding aripiprazole to your current antipsychotic medication can help with weight gain and metabolic side effects. It is for women aged 18 to 65 who have schizophrenia or schizoaffective disorder and are currently taking olanzapine, clozapine, or risperidone.

Hear when a new Antipsychotic-induced Weight Gain (AIWG) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.